Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate

Autor: George A W Bruyn, Attila Pethö-Schramm, Ed N. Griep, Michelle E A Borm, Marjolein J H de Hair, Ruth Klaasen, Maxime M A Verhoeven, Jacob M van Laar, Johannes W. J. Bijlsma, Paco M J Welsing, Janneke Tekstra, Floris P J G Lafeber, Reinhard Bos, Johannes W G Jacobs

Publikováno v: Rheumatology (Oxford, England)

Objectives U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d519f37c12e2ec2597aef199d7ee1f5c
http://europepmc.org/articles/PMC7449801

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: Results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Autor: Calin D. Popa, Dirkjan van Schaardenburg, Ed N. Griep, Mirian Starmans-Kool, D. Marsman, Laurette van Boheemen, Michael T. Nurmohamed, Wouter H Bos, Alper M. van Sijl, Marian H. van Beers-Tas, Samina A. Turk, Maarten Boers

Publikováno v: RMD Open, 7(1):e001591. BMJ Publishing Group
RMD open, 7(1):e001591. BMJ Publishing Group
RMD Open, Vol 7, Iss 1 (2021)
RMD Open
van Boheemen, L, Turk, S, Beers-Tas, M V, Bos, W, Marsman, D, Griep, E N, Starmans-Kool, M, Popa, C D, van Sijl, A, Boers, M, Nurmohamed, M T & van Schaardenburg, D 2021, ' Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: Results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial ', RMD Open, vol. 7, no. 1, e001591 . https://doi.org/10.1136/rmdopen-2021-001591

ObjectivesPersons at high risk of rheumatoid arthritis (RA) might benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying effects of statins in patients with RA as well as an a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a52ebb5bb7e0e3ad5eef3550b93c042
https://research.vumc.nl/en/publications/216fdbf1-4b47-49aa-9b2f-da296778c04b

Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis

Autor: Ed N. Griep, Hendrika Bootsma, F. Maas, Anneke Spoorenberg, Elisabeth Brouwer, Eveline van der Veer, F. Wink, Suzanne Arends, George A W Bruyn

Publikováno v: The Journal of Rheumatology, 44(5), 587-593. J RHEUMATOL PUBL CO

Objective.To assess structural and inflammatory ultrasound (US) lesions of entheses in ankylosing spondylitis (AS) patients with active disease and to evaluate inflammatory lesions after 6 months of tumor necrosis factor (TNF-α) blocking therapy, in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a38c382781604aabd4ce2c644096ff4
https://doi.org/10.3899/jrheum.160584

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project

Autor: Dirkjan van Schaardenburg, Maaike Heslinga, Alexandre E. Voskuyl, Rob Schotsman, Ed N. Griep, Willem F. Lems, Inge A. M. van den Oever, Micheal T. Nurmohamed, Yvo M. Smulders, Ben A. C. Dijkmans, Mike J L Peters, H. Griep-Wentink, Maarten Boers, Walter Cambach

Publikováno v: van den Oever, I A M, Heslinga, M, Griep, E N, Griep-Wentink, H R M, Schotsman, R, Cambach, W, Dijkmans, B A C, Smulders, Y M, Lems, W F, Boers, M, Voskuyl, A E, Peters, M J L, van Schaardenburg, D & Nurmohamed, M T 2017, ' Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project ', Rheumatology, vol. 56, no. 9, pp. 1472-1478 . https://doi.org/10.1093/rheumatology/kew497
Rheumatology, 56(9), 1472-1478. Oxford University Press
Rheumatology (Oxford, England), 56(9), 1472-1478. Oxford University Press

Objective To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA. Methods Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e47a24060d9c627707aa4b98c0ad05
https://research.vumc.nl/en/publications/c63f2254-3396-4057-a474-35894bbe32d8

SAT0416 Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab

Autor: Michael T. Nurmohamed, Sjoerd C. Heslinga, Marc R. Kok, M. Verhoef, Ed N. Griep, Andreas H. Gerards, I E van der Horst-Bruinsma, C. Koehorst, Anna M. Schilder

Publikováno v: Annals of the Rheumatic Diseases. 75:820.3-821

Background Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective in the treatment of AS (2). We have shown earlier that treatment with adalimum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51b621c1b82ff3d295f60009525deade
https://doi.org/10.1136/annrheumdis-2016-eular.3376